These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33777676)

  • 1. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
    Wang Z; Kang W; Li O; Qi F; Wang J; You Y; He P; Suo Z; Zheng Y; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):694-707. PubMed ID: 33777676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 4. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
    Li B; Wang B
    Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity
    Liu Y; Liu X; Zhang N; Yin M; Dong J; Zeng Q; Mao G; Song D; Liu L; Deng H
    Acta Pharm Sin B; 2020 Dec; 10(12):2299-2312. PubMed ID: 33354502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
    Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
    Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP.
    Holowaty MN; Sheng Y; Nguyen T; Arrowsmith C; Frappier L
    J Biol Chem; 2003 Nov; 278(48):47753-61. PubMed ID: 14506283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
    Jingjing W; Wenzheng G; Donghua W; Guangyu H; Aiping Z; Wenjuan W
    Cancer Med; 2018 Aug; 7(8):4004-4011. PubMed ID: 29992764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
    Fan Z; Wu C; Chen M; Jiang Y; Wu Y; Mao R; Fan Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1041-1053. PubMed ID: 35530130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Insight Into p53-Inhibiting Genes in Epstein–Barr Virus-Associated Gastric Adenocarcinoma.
    Hashemi SMA; Moradi A; Hosseini SY; Razavi Nikoo H; Bamdad T; Faghih Z; Sarvari J; Tabarraei A
    Iran Biomed J; 2023 Jan; 27(1):34-45. PubMed ID: 36624687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
    Yang H; Zhang X; Lao M; Sun K; He L; Xu J; Duan Y; Chen Y; Ying H; Li M; Guo C; Lu Q; Wang S; Su W; Liang T; Bai X
    Cell Death Differ; 2023 Feb; 30(2):560-575. PubMed ID: 36539510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer.
    Li N; Geng F; Liang SM; Qin X
    Cell Signal; 2022 Aug; 96():110351. PubMed ID: 35523402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective.
    Korenev G; Yakukhnov S; Druk A; Golovina A; Chasov V; Mirgayazova R; Ivanov R; Bulatov E
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
    Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
    J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7.
    Holowaty MN; Zeghouf M; Wu H; Tellam J; Athanasopoulos V; Greenblatt J; Frappier L
    J Biol Chem; 2003 Aug; 278(32):29987-94. PubMed ID: 12783858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.